Thirty Days, Three Months, or Somewhere Between: DAPT After a Carotid Stent
AHA and SVS say thirty days is enough. The European vascular society says three months. Neither is wrong, and the gap between them is where his actual prescription has to land.
T.R., a 68-year-old man, coached high-school football for over thirty years and still shows up most Saturdays to help run drills for the freshman team, three years after officially retiring. He has longstanding hypertension, well controlled on lisinopril, and quit smoking a decade ago after his own cardiologist finally got through to him. He has no diabetes and no prior stroke, and until three weeks ago had never had a cardiovascular event of any kind despite the stenosis apparently building for years. Three weeks ago he had a transient ischemic attack — left-arm weakness and word-finding trouble that resolved within twenty minutes — and workup found severe right internal carotid stenosis; he underwent carotid artery stenting and has been on aspirin and clopidogrel since.
He is back for his three-week follow-up asking, reasonably, how much longer he needs to take both. The honest answer is that the guidelines disagree with each other. The AHA and Society for Vascular Surgery (SVS) recommend dual antiplatelet therapy (DAPT) for at least thirty days after stenting; the European Society for Vascular Surgery (ESVS) recommends three months. Real-world prescribing reflects that same lack of consensus — national registry data show roughly a fifth of patients stopped before three months, a third continued three to six, and nearly half stayed on both drugs past six months, with longer duration associated with lower rates of stroke readmission but a measurably higher rate of extracranial, and possibly intracranial, bleeding. A recent nationwide cohort study found short-duration therapy performed no differently than long-duration on efficacy or adverse events overall — though its short arm still ran at least ninety days, so it speaks to three-versus-six months and not to anything shorter. Suggestive, but not the randomized trial that would actually settle which duration is right for a specific patient rather than a population average.
At the 3-week post-CAS follow-up
AHA and SVS both set the floor at thirty days, and he's already past that with no complications. I'd lean toward stopping clopidogrel around the one-month mark and continuing aspirin indefinitely — the shorter end of the guideline range, given he has no other indication pushing toward longer dual therapy.
I'd weigh the European guideline more heavily here — three months, not thirty days. The registry data showing lower stroke readmission with longer duration is real, even if it's associational rather than randomized, and a man who just had a TIA from this same lesion is exactly the patient that signal is about.
I recognize the same data shows more extracranial bleeding with longer duration, and I don't think that risk is trivial — I just think it's a more acceptable trade against a second cerebrovascular event than against a bleed that's usually manageable.
I don't think either duration is indefensible, and I want to name that directly rather than pretend one guideline is simply correct. Given he's active enough that a fall or a knock during a coaching drill isn't hypothetical for him, and given the newer nationwide cohort data found no real efficacy difference between short and long duration, I'd land at eight weeks — longer than the AHA/SVS floor, short of the full three months — and revisit sooner if anything changes.
Clopidogrel continued to approximately 8 weeks post-procedure, then discontinued; aspirin 81 mg continued indefinitely. Follow-up scheduled to coincide with the stopping point.
Not settled by guideline consensus, and named as such rather than presented as resolved:
Both physicians agreed the underlying disagreement between AHA/SVS and ESVS reflects a genuine absence of randomized head-to-head evidence for DAPT duration after carotid stenting, not a case where one society simply has it right — the 8-week compromise reflected his specific risk profile, not a general answer for every patient in this situation.